Overview

Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized and multi-center study to compare the efficacy and safety of continued enfuvirtide (Fuzeon) plus (+) OB therapy versus OB alone in participants with HIV-1 infection. Participants will receive an initial 28 week induction treatment with enfuvirtide + OB. After 28 weeks participants with a plasma viral load less than or equal to (Phase: Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Anti-Retroviral Agents
Enfuvirtide